Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroblastoma 1 Myelodysplastic Syndromes 1 Mesothelioma, Malignant 1 Mesothelioma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Hodgkin Disease 1 Ganglioneuroblastoma 1

Interventions

Cyclophosphamide 13 Temozolomide 10 Magnetic Resonance Spectroscopy 10 dinutuximab 8 X-Rays 8 Specimen Handling 8 Irinotecan 8 Biopsy 8 Phantoms, Imaging 7 Topotecan 6 Nuclear Medicine Department, Hospital 6 fludarabine 5 Vincristine 5 3-Iodobenzylguanidine 5 fludarabine phosphate 4 Granulocyte-Macrophage Colony-Stimulating Factor 4 Etoposide 4 tipifarnib 3 sargramostim 3 Radiotherapy 3 Melphalan 3 Isotretinoin 3 Filgrastim 3 Doxorubicin 3 Carboplatin 3 ulixertinib 2 tazemetostat 2 selpercatinib 2 saponin QA-21V1 2 pembrolizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroblastoma × Influenza Vaccines × 90 days × Clear all

NCT07502287 2026-03-30

DUAL-NK-NB

Beijing Biotech

Phase 1/2 Recruiting

Neuroblastoma, Recurrence, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡